Enzymotec Ltd (ENZY) Receives Consensus Recommendation of “Hold” from Brokerages

Enzymotec Ltd (NASDAQ:ENZY) has been given an average rating of “Hold” by the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.75.

ENZY has been the topic of several research reports. Jefferies Group restated a “hold” rating and set a $11.50 price target on shares of Enzymotec in a research report on Thursday, October 19th. Zacks Investment Research upgraded Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Wells Fargo & Co boosted their target price on Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a report on Monday, October 30th. Finally, BidaskClub downgraded Enzymotec from a “hold” rating to a “sell” rating in a report on Saturday.

A number of institutional investors have recently added to or reduced their stakes in the business. State Street Corp boosted its holdings in Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 380 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Enzymotec in the third quarter worth $107,000. Osborn Williams & Donohoe LLC bought a new stake in Enzymotec in the third quarter worth $137,000. Finally, Janus Henderson Group PLC bought a new stake in Enzymotec in the second quarter worth $2,350,000. 15.73% of the stock is currently owned by institutional investors and hedge funds.

Enzymotec (NASDAQ:ENZY) remained flat at $$11.85 during midday trading on Friday. 54,689 shares of the company traded hands, compared to its average volume of 101,553. Enzymotec has a 52-week low of $6.30 and a 52-week high of $12.35. The company has a market capitalization of $277.62, a P/E ratio of -43.89, a price-to-earnings-growth ratio of 3.19 and a beta of 1.22.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/06/enzymotec-ltd-enzy-receives-consensus-recommendation-of-hold-from-brokerages.html.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply